Phase II Trial of Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer
Upon determination of eligibility, all patients will be receive:
- Topotecan
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate
Anthony Greco, MD
Principal Investigator
Sarah Cannon Research Institute
United States: Food and Drug Administration
SCRI LUN 66
NCT00193388
September 2002
February 2007
Name | Location |
---|